Candriam S.C.A. Buys 95,972 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Candriam S.C.A. raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 96.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 195,347 shares of the biotechnology company's stock after acquiring an additional 95,972 shares during the quarter. Candriam S.C.A. owned approximately 0.34% of Ascendis Pharma A/S worth $26,640,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Gilbert & Cook Inc. lifted its stake in shares of Ascendis Pharma A/S by 8.4% during the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company's stock worth $357,000 after purchasing an additional 220 shares during the last quarter. Jump Financial LLC purchased a new stake in Ascendis Pharma A/S in the fourth quarter valued at about $1,681,000. Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S by 20.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company's stock valued at $191,346,000 after buying an additional 254,749 shares during the last quarter. First Turn Management LLC purchased a new stake in Ascendis Pharma A/S in the fourth quarter valued at about $19,092,000. Finally, Quadrant Capital Group LLC raised its stake in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after buying an additional 151 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on ASND shares. Stifel Nicolaus started coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They set a "buy" rating and a $200.00 target price on the stock. Cantor Fitzgerald dropped their target price on Ascendis Pharma A/S from $173.00 to $170.00 and set an "overweight" rating on the stock in a report on Wednesday. Bank of America raised their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group raised their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating on the stock in a report on Wednesday. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $187.08.

Ascendis Pharma A/S Trading Up 0.1 %

ASND stock traded up $0.15 on Friday, hitting $119.15. 625,894 shares of the company's stock traded hands, compared to its average volume of 393,567. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63. The stock has a fifty day moving average of $134.38 and a 200-day moving average of $137.94.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.